Core Insights - Phio Pharmaceuticals Corp. is set to present its INTASYL siRNA drug technology at the Advanced Therapies USA 2025 Congress, highlighting its potential in cancer treatment [1][2] - The INTASYL technology aims to down-regulate gene expression, with a specific focus on the PH-762 compound for treating cutaneous carcinomas [2][3] Company Overview - Phio Pharmaceuticals is a clinical-stage siRNA biopharmaceutical company that specializes in immuno-oncology therapeutics using its proprietary INTASYL® gene silencing technology [3] - The lead clinical program, PH-762, targets the PD-1 gene associated with various skin cancers and is currently undergoing a Phase 1b trial for cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma [3] Presentation Details - The podium presentation titled "INTASYL® Synthesized siRNA Drug Technology" will take place on November 18, 2025, at 1:15 PM EDT in the Innovation Showcase at the Pennsylvania Convention Center [2] - Melissa Maxwell, M.S., will be the presenting author, emphasizing the significance of INTASYL technology in enhancing cancer treatment [2]